RecruitingNCT06234332

Peking University Birth Cohort in Weifang (PKUBC-WF)

Peking University Birth Cohort in Weifang

Sponsor

Peking University

Enrollment

2,800 participants

Start Date

Feb 1, 2024

Study Type

OBSERVATIONAL

Conditions

Obesity Pregnancy Outcomes Anemia Mother-Infant Interaction Child Development Gestational Diabetes Preterm Birth Gestational Hypertension Health Problems in Pregnancy

Summary

The PKUBC-WF is a prospective cohort study carried out in Weifang city of Shandong, China. The primary aim of this study is to investigate the short-term and long-term effects of pre-pregnant and prenatal exposure on maternal and child health. Data are collected regarding environmental, nutritional and lifestyle exposures as well as short-term and long-term health outcomes of mothers and their children from birth to before 18 years old. Biological samples including peripheral blood, urine, placenta, umbilical cord, cord blood, and faeces are also collected.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a long-term pregnancy and birth study based in Weifang, China (run in partnership with Peking University) that will follow mothers, fathers, and children from early pregnancy through childhood to understand how environment and genetics affect health. **You may be eligible if...** - You are a pregnant woman between 6 and 14 weeks of pregnancy - You have lived in Weifang for at least the past 6 months and plan to stay after delivery - You plan to receive pregnancy care and give birth at Weifang Maternal and Child Hospital - The biological father is also willing to participate - Children born to enrolled mothers are also eligible to participate **You may NOT be eligible if...** - You are unable to communicate normally Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.